Press Releases

YEAR
Toggle Summary Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted a non-statutory stock option
View HTML
Toggle Summary Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the appointment of Dr.
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at IDWeek 2021
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data presentation at
View HTML
Toggle Summary Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient’s Pharmacy Network Program
- Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) DUBLIN, Ireland and FORT WASHINGTON, Pa. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and
View HTML
Toggle Summary Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner,
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
DUBLIN, Ireland and FORT WASHINGTON, Pa. , Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China , commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd (SPC)- -Conference call
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com